Progress in RadioGel® Cancer Therapy Trials

April 15, 2025 — Vivos Inc. has reported ongoing progress in its human clinical trials for RadioGel®, a precision radionuclide therapy designed to target and treat solid tumors. The therapy has been designated a Breakthrough Device by the FDA due to its potential to significantly improve cancer treatment outcomes.

RadioGel® is a cutting-edge cancer therapy that delivers targeted radiation directly to the tumor site. This precision approach minimizes damage to surrounding healthy tissue, which is a common issue in traditional cancer treatments like chemotherapy and external radiation therapy. Early results from the clinical trials in India have shown promising efficacy in treating various types of solid tumors, including those resistant to conventional treatments.

Breakthrough Designation and Potential

The FDA’s Breakthrough Device designation underscores the potential of RadioGel® to bring a new treatment option to patients suffering from cancers that are difficult to treat with existing therapies. Vivos Inc. is optimistic about the future of the drug, which could pave the way for new cancer therapies, improving survival rates and quality of life for patients worldwide.

Clinical Trials in India

The ongoing human clinical trials in India are focused on demonstrating the safety and efficacy of RadioGel® in patients with solid tumors. India, with its large population and rising cancer cases, serves as a key location for these trials. The results from these trials could lead to a broader global rollout of RadioGel® for patients in need of advanced cancer treatment options.

Key Benefits of RadioGel®

Targeted Treatment: Delivers radiation directly to the tumor site, sparing surrounding healthy tissue.
Minimized Side Effects: Patients experience fewer side effects compared to traditional therapies.
Breakthrough Device: FDA designation accelerates development and approval process.
High Efficacy: Early results show promising responses in difficult-to-treat solid tumors.

What’s Next for RadioGel®?

As Vivos Inc. moves forward with its clinical trials, the company plans to expand its research into additional cancer types and refine the delivery mechanisms for enhanced precision. With the ongoing success of the trials, there is growing optimism in the medical community about the future of RadioGel® as a revolutionary cancer treatment.